Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/16206
Title: The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
Authors: Mellon, JK
First Published: Sep-2005
Citation: EUR J CANCER, 2005, 41 (13), pp. 2016-2022
Abstract: In 2003, the first of two large NCI-sponsored prostate cancer chemoprevention trials was reported. The prostate cancer prevention trial (PCPT) demonstrated a 24.8% reduction in the prevalence of prostate cancer in men taking finasteride 5mg/d for 7 years. However, despite the overall reduced risk of prostate cancer, men in the finasteride-treated arm of the study were more likely to develop high-grade disease. This article examines some of the controversies aroused by the PCPT and evaluates some of the arguments that have been advanced in an attempt to explain some of the unexpected outcomes of the study. In addition, some of the recent studies assessing the potential impact of an effective chemopreventive strategy on population mortality are reviewed. To conclude, there is some discussion of factors, which need to be openly discussed with male patients who might be considered for finasteride therapy.
DOI Link: 10.1016/j.ejca.2005.06.010
ISSN: 0959-8049
Links: http://hdl.handle.net/2381/16206
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.